Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation.

By H. Tse, Y. Kwong, J. Chan, G. Lo, C. Ho, C. Lau. The Lancet, 2003

911 citations recorded by the source corpus.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/8a3ce7c06bd33afc3b86415c652b2dbace7fd6c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Surgery

Citations in the corpus

Unchain my heart: the scientific foundations of cardiac repair. (2005, background): “8 Endocardial injection, guided BMCs 40 ml/Ficoll/none Not reported + Wall motion and thickening ↑; (25) by electromechanical mapping hypoperfusion ↓”
Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. (2005, background): “Despite the recent negative reports about transdifferentiation (3, 16, 36), clinical trials with bone marrow-derived cell populations have been published and in part proven effective in the treatment of myocardial infarction (31, 33, 39).”
Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy (2005, background): “20–22 The angiogenic potential of MNCs is mediated at least in part by production by the cells of a variety of angiogenic factors.”
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration (2003, background): “, or by guided electrochemical mapping directly into infarcted myocardiu”
Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure (2003, background): “Patients were not enrolled in the study if any 1 of the following exclusion criteria was met: (1) difficulty in obtaining vascular access for percutaneous procedures; (2) previous or current history of neoplasia or other comorbidity that could impact the patient’s short-term survival; (3) significan”
Adult cardiac stem cells are multipotent and support myocardial regeneration. (2003, result): “Alternatively, it et al., 2002; Tse et al., 2003; Perin et al., 2003) based,is possible that cardiogenesis and cardiac regeneration in part, on our early results with myocardial regenerationmight result from distinct differentiation programs, as is with bone marrow derived cells (Orlic et al.,…”
Mesenchymal Stem Cells for Regenerative Medicine (2019, background): “Furthermore, MSC therapy has been intensively investigated as a treatment for myocardial infarction [147], peripheral ischemic vascular diseases [148], dilated cardiomyopathy [138], and pulmonary hypertension [149].”
Autologous mesenchymal stem cell transplantation in stroke patients (2005, methodology): “Patients between 30 and 75 years old were eligible for the study if they had the following characteristics: (1) they had been observed within 7 days of the onset of symptoms; ( 2 ) there were relevant lesions within the MCA territory as assessed using diffusion-weighted imaging (DWI); and (3) they h”
Plasticity of marrow-derived stem cells. (2003, positive): “based on medication usage, quality of life, and MRI-based studies of function at the site of injection.(41) In a separate study, after autologous AC133+ BM cells were injected into infarct borders following coronary artery bypass grafting, there may have been improved perfusion and cardiac function.”
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium (2004, background): “Our data are of particular importance given the fact that a variety of groups worldwide have initiated clinical trials of BM transplantation into ischaemic myocardiu”